1. Home
  2. ARVN
  3. ARVN News

Latest Arvinas Inc. (ARVN) News on June 15, 2025

ARVN

MT Newswires

2 days ago

Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
ARVN

GlobeNewswire

2 days ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

ARVN

MT Newswires

8 days ago

Sector Update: Health Care Stocks Advance Premarket Friday

ARVN

MT Newswires

9 days ago

Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
ARVN

GlobeNewswire

9 days ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
ARVN

GlobeNewswire

9 days ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

ARVN

MT Newswires

13 days ago

Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
ARVN

GlobeNewswire

15 days ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
ARVN

BioPharma Dive

15 days ago

Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer

Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?
ARVN

Zacks

15 days ago

Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect?

Arvinas to Present at Jefferies Global Healthcare Conference
ARVN

GlobeNewswire

16 days ago

Arvinas to Present at Jefferies Global Healthcare Conference

Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
ARVN

Clinical Trials Arena

16 days ago

Pfizer and Arvinas gamble to shift breast cancer treatment paradigm

ARVN

MT Newswires

a month ago

UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating

ARVN

MT Newswires

a month ago

Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating

ARVN

MT Newswires

a month ago

Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
ARVN

Simply Wall St.

a month ago

Arvinas, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)
ARVN

Insider Monkey

a month ago

Here are 1 Main Capital Partners’ Views on Arvinas (ARVN)

ARVN

MT Newswires

a month ago

TD Cowen Downgrades Arvinas to Hold From Buy

ARVN

MT Newswires

a month ago

Jefferies Downgrades Arvinas to Hold From Buy, Adjusts Price Target to $10 From $52

Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...
ARVN

GuruFocus.com

a month ago

Arvinas Inc (ARVN) Q1 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ...

Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates
ARVN

Zacks

a month ago

Arvinas, Inc. (ARVN) Q1 Earnings and Revenues Beat Estimates

ARVN

MT Newswires

a month ago

Top Premarket Decliners

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda
ARVN

BioPharma Dive

a month ago

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

a month ago

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ARVN

Zacks

2 months ago

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
ARVN

GlobeNewswire

2 months ago

Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
ARVN

GlobeNewswire

2 months ago

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
ARVN

GlobeNewswire

2 months ago

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting
ARVN

GlobeNewswire

2 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple
ARVN

Insider Monkey

2 months ago

Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)
ARVN

Zacks

2 months ago

After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN)

ARVN

MT Newswires

2 months ago

Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
ARVN

Benzinga

2 months ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s
ARVN

Clinical Trials Arena

2 months ago

Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s

ARVN

MT Newswires

2 months ago

Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
ARVN

GlobeNewswire

2 months ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
ARVN

Simply Wall St.

2 months ago

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases
ARVN

GlobeNewswire

3 months ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
ARVN

Zacks

3 months ago

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?
ARVN

Insider Monkey

3 months ago

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds?

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
ARVN

Zacks

3 months ago

Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround
ARVN

Zacks

3 months ago

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround

Biotech Alert: Searches spiking for these stocks today
ARVN

TipRanks

3 months ago

Biotech Alert: Searches spiking for these stocks today

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
ARVN

Zacks

3 months ago

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
ARVN

Zacks

3 months ago

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?
ARVN

Zacks

3 months ago

Arvinas (ARVN) Moves 8.8% Higher: Will This Strength Last?

ARVN

MT Newswires

3 months ago

Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70

ARVN

MT Newswires

3 months ago

Arvinas' Vepdegestrant Likely to Have 'Restricted Label' in Breast Cancer, Wedbush Says

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study
ARVN

Zacks

3 months ago

ARVN Stock Plunges 53% Following Mixed Data From Breast Cancer Study

ARVN

MT Newswires

3 months ago

Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
ARVN

Investor's Business Daily

3 months ago

Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug

ARVN

MT Newswires

3 months ago

Citigroup Cuts Arvinas' Price Target to $10 From $19, Maintains Neutral Rating

ARVN

MT Newswires

3 months ago

Top Midday Decliners

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
ARVN

Clinical Trials Arena

3 months ago

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients

ARVN

MT Newswires

3 months ago

Oppenheimer Downgrades Arvinas to Perform From Outperform

ARVN

MT Newswires

3 months ago

Sector Update: Health Care

ARVN

MT Newswires

3 months ago

Arvinas, Pfizer Say Vepdegestrant Trial Meets Primary Endpoint in Breast Cancer With ESR1 Mutations

ARVN

MT Newswires

3 months ago

Top Premarket Decliners

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
ARVN

GlobeNewswire

3 months ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

3 months ago

Arvinas to Participate in Upcoming Investor Conferences

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know
ARVN

Zacks

3 months ago

Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know

ARVN

MT Newswires

4 months ago

Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago
ARVN

Simply Wall St.

4 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy
ARVN

Zacks

4 months ago

All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%
ARVN

Zacks

4 months ago

How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09%

ARVN

MT Newswires

4 months ago

Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating

ARVN

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Arvinas Inc Earnings Call

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...
ARVN

GuruFocus.com

4 months ago

Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ...

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
ARVN

Zacks

4 months ago

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

ARVN

MT Newswires

4 months ago

Arvinas' Q4 Loss Narrows, Revenue Misses Analysts' Expectations

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

4 months ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings
ARVN

GuruFocus.com

4 months ago

What To Expect From Arvinas Inc (ARVN) Q4 2024 Earnings

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
ARVN

GlobeNewswire

4 months ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
ARVN

Motley Fool

5 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

ARVN

MT Newswires

5 months ago

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
ARVN

GlobeNewswire

5 months ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial
ARVN

Clinical Trials Arena

6 months ago

Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
ARVN

Benzinga

6 months ago

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

ARVN

MT Newswires

6 months ago

Arvinas, Pfizer Present 'Encouraging' Preliminary Data for Prospective Breast Cancer Treatment

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
ARVN

GlobeNewswire

6 months ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
ARVN

Insider Monkey

6 months ago

Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
ARVN

GlobeNewswire

7 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
ARVN

GlobeNewswire

7 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode
ARVN

Insider Monkey

7 months ago

Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

7 months ago

Arvinas to Participate in Upcoming Investor Conferences

Arvinas Third Quarter 2024 Earnings: Beats Expectations
ARVN

Simply Wall St.

7 months ago

Arvinas Third Quarter 2024 Earnings: Beats Expectations

ARVN

MT Newswires

7 months ago

UBS Adjusts Price Target on Arvinas to $74 From $82, Maintains Buy Rating

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...
ARVN

GuruFocus.com

7 months ago

Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ...

ARVN

MT Newswires

7 months ago

Arvinas' Q3 Net Loss Narrows, Revenue Rises

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates
ARVN

Zacks

7 months ago

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
ARVN

GlobeNewswire

8 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings
ARVN

GuruFocus.com

8 months ago

Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely
ARVN

Simply Wall St.

8 months ago

We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential
ARVN

Insider Monkey

8 months ago

Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
ARVN

GlobeNewswire

8 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
ARVN

GlobeNewswire

8 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago
ARVN

Simply Wall St.

9 months ago

Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares
ARVN

GuruFocus.com

9 months ago

Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now
ARVN

Insider Monkey

9 months ago

Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Arvinas to Participate in Upcoming Investor Conferences
ARVN

GlobeNewswire

10 months ago

Arvinas to Participate in Upcoming Investor Conferences

Share on Social Networks: